title: Histologic parameters predictive of disease outcome in women with advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy.
abstract: The use of neoadjuvant chemotherapy followed by tumor reduction surgery, also called interval debulking surgery (IDS), is considered an alternative therapeutic regimen for selected patients with advanced stage epithelial ovarian cancer (EOC). Although minimal residual disease has been proven to be a prognostic factor in traditional cytoreduction for advanced stage EOC, predictive factors after IDS still remain unexplored. The aim of this study was to determine the prognostic value of post-neoadjuvant histologic changes with clinical outcome. Three pathologists evaluated 67 cases for the following parameters: fibrosis, necrosis, residual tumor, and inflammation. The Cohen's kappa statistic was used to measure agreement among pathologists. Univariate and multivariate Cox proportional hazards models were used to determine the association between histologic parameters and recurrence-free survival (RFS) and overall survival (OS). There was substantial to almost perfect agreement among the three pathologists in all four histologic parameters (k ranged from 0.65 to 0.97). Fibrosis was associated with longer RFS (P = 0.0257) with a median of 20 months for tumors with fibrosis (3+) versus 12 months for tumors with fibrosis (1+, 2+) and longer OS (P = 0.0249) with a median of 51 months for tumors with fibrosis (3+) versus 32 months for tumors with fibrosis (1+, 2+). Our results revealed that patients with tumors exhibiting fibrosis (1+, 2+), as well as necrosis (0, 1+), had significant shorter RFS and OS (P = 0.059 and P = 0.0234, respectively). We suggest that the assessment of fibrosis and necrosis should be implemented in pathologic evaluation and prospectively validated in future studies.
authors: Department of Pathology, University of Southern California, Los Angeles, CA.
authors: Damanzoopinder
authors: D
authors: Samrao
authors: Dan
authors: D
authors: Wang
authors: Faith
authors: F
authors: Ough
authors: Yvonne G
authors: YG
authors: Lin
authors: Song
authors: S
authors: Liu
authors: Teodulo
authors: T
authors: Menesses
authors: Annie
authors: A
authors: Yessaian
authors: Nicole
authors: N
authors: Turner
authors: Tanja
authors: T
authors: Pejovic
authors: Paulette
authors: P
authors: Mhawech-Fauceglia
references: Cancer. 2003 Oct 1;98(7):1521-30
references: 14508841
references: Ann Surg Oncol. 2005 Mar;12(3):228-36
references: 15827815
references: J Clin Oncol. 2007 Aug 20;25(24):3621-7
references: 17704411
references: Clin Orthop Relat Res. 2007 Feb;455:219-24
references: 17016226
references: J Clin Oncol. 2005 Dec 1;23(34):8688-96
references: 16246976
references: Am J Surg Pathol. 2007 Jan;31(1):58-64
references: 17197919
references: Am J Surg Pathol. 2004 Feb;28(2):215-23
references: 15043311
references: Cancer. 1994 Jun 1;73(11):2680-6
references: 8194005
references: N Engl J Med. 2010 Sep 2;363(10):943-53
references: 20818904
references: J Clin Pathol. 2002 Jan;55(1):27-31
references: 11825920
references: Mod Pathol. 2009 Dec;22(12):1555-63
references: 19801967
references: Chest. 2001 Nov;120(5):1584-91
references: 11713138
references: J Clin Pathol. 2008 May;61(5):652-7
references: 18006668
references: Int J Oncol. 2007 Mar;30(3):727-34
references: 17273775
references: Arch Pathol Lab Med. 2012 Jan;136(1):100-9
references: 22208494
references: J Surg Oncol. 2002 May;80(1):4-11
references: 11967899
references: Am J Clin Pathol. 2008 Jan;129(1):13-23
references: 18089485
references: Ann Oncol. 2005;16 Suppl 8:viii7-viii12
references: 16239238
references: Ann Surg Oncol. 2005 Mar;12(3):214-21
references: 15827813
references: Acta Oncol. 2006;45(4):469-75
references: 16760184
references: Am J Clin Pathol. 2008 Feb;129(2):252-62
references: 18208806